Drug arrives years after pandemic’s peak, but could still offer critical protection to vulnerable populations.

Drug arrives years after pandemic’s peak, but could still offer critical protection to vulnerable populations.

Ensitrelvir has already been approved as a prophylactic in Japan, with an FDA decision in the U.S. expected soon.